Home › Research › Biomarkers
Cannabidiol for chronic neuroinflammation: clinical pharmacology and what an interpretable trial will require
Soderstrom K, Litwa KA.. Authorea Preprints, 2026-10-05
Topic: Gut, metabolism and diet
Plain-language summary
Public interest in cannabinoid medicines has outpaced the clinical pharmacology needed to judge product, dose and route. In the United States the only fully approved plant-derived cannabinoid is purified cannabidiol (CBD) oral solution (Epidiolex, United States; Epidyolex, EU), indicated for three rare epilepsies. Approval trials showed oral CBD can be titrated to effective concentrations, with a large food effect, established drug interactions and hepatic effects warranting scheduled monitoring. Preclinical work, including circuit-level studies, suggests anti-inflammatory effects on microglia and astrocytes at similar daily doses. This raises the possibility of testing CBD in unresolved chronic neuroinflammation, a glial-mediated driver of progression in early-onset dementias. Chronic neuroinflammation is failed resolution of an initial primary inflammatory response. Except where the blood-brain barrier is breached, it is largely independent of peripheral immunity. Single-target anti-inflammatories often fail for distinct reasons: many never reach adequate CNS concentrations; those that do may engage only one of many potentially redundant pathways; and suppression can block resolution as well as injury. Unlike Δ9-tetrahydrocannabinol (dronabinol), CBD is not an intoxicating CB1 agonist, but after systemic dosing it reaches the brain and can modulate inflammatory signaling through several systems. Evidence outside epilepsy is limited, partly because many small studies used uncharacterized products, unstandardized meals and no plasma concentrations. This narrative review is not a systematic survey. An interpretable next clinical trial needs one characterized CBD preparation, meal-standardized with oral dosing, pre-specified interaction and liver monitoring, a functional outcome that can change within months, and a co-signal such as blood GFAP.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Soderstrom, K., & Litwa, K. A. (2026). Cannabidiol for chronic neuroinflammation: clinical pharmacology and what an interpretable trial will require. Authorea Preprints. https://doi.org/10.22541/authorea.15009897/v1
Vancouver
Soderstrom K, Litwa KA. Cannabidiol for chronic neuroinflammation: clinical pharmacology and what an interpretable trial will require. Authorea Preprints. 2026. doi:10.22541/authorea.15009897/v1.
BibTeX
@article{soderstrom2026-f55806d2,
author = {Soderstrom, K. and Litwa, K. A.},
title = {{Cannabidiol for chronic neuroinflammation: clinical pharmacology and what an interpretable trial will require}},
journal = {Authorea Preprints},
year = {2026},
doi = {10.22541/authorea.15009897/v1},
url = {https://doi.org/10.22541/authorea.15009897/v1}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Single-target anti-inflammatories often fail for distinct reasons: many never reach adequate CNS concentrations; those that do may engage only one of many potentially redundant pathways; and suppression can block resolution as well as injury.
- Unlike Δ9-tetrahydrocannabinol (dronabinol), CBD is not an intoxicating CB1 agonist, but after systemic dosing it reaches the brain and can modulate inflammatory signaling through several systems.
- Evidence outside epilepsy is limited, partly because many small studies used uncharacterized products, unstandardized meals and no plasma concentrations.
- This narrative review is not a systematic survey.
- An interpretable next clinical trial needs one characterized CBD preparation, meal-standardized with oral dosing, pre-specified interaction and liver monitoring, a functional outcome that can change within months, and a co-signal such as blood GFAP.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designnarrative review
- Evidence strengthLow
How this study scored 16/100
Preprint — not yet peer-reviewed. It scored 21 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 13 of the 62 points we could judge it on, which is 21 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (Authorea Preprints) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 0 / 12 | Design recorded as “narrative review”, which our rubric does not rank (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 4 / 10 | Preprint — not yet peer-reviewed. Hosted on a preprint server. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 13 / 62 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 13 of the 62 points we could judge it on is 21 out of 100. |
| Total | 21 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “plants”
117 studies in the library carry the topic tag “plants”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 117 tagged studies.